Risk factor modification & medical therapy

in Atherosclerosis and Risk Factors

Applied

Type

Reinforcement

Confidence

90%

Created

Mar 18, 2026

Evidence

1 source

Rationale

The 2023 AHA Heart Disease and Stroke Statistics update provides the most current epidemiological data supporting the critical role of managing hypertension, diabetes, and dyslipidemia in reducing the global burden of cardiovascular disease. This evidence was integrated to reinforce the existing clinical recommendations. Additionally, all medical abbreviations were expanded on first use as per the editorial instructions.

Evidence

Tsao CW et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023. PMID: 36695182.
Verified source
PubMedDOI

Content Changes

* **Risk factor modification:** Includes aggressive management of hypertension,hypertension diabetes,(HTN), diabetes mellitus (DM), and dyslipidemia to target levels, alongside smoking cessation. These factors remain the primary drivers of cardiovascular disease (CVD) burden globally [@tsao2023].
* **Medical therapy:** Antiplatelet therapy and high-intensity statins are recommended.recommended for patients with peripheral artery disease (PAD). Cilostazol improves walking distance but is not available in all regions; pentoxifylline has limited evidence.

**Note on renal artery stenosis:** Routine revascularization for atherosclerotic renal artery stenosis is NOT recommended based on CORAL and ASTRAL trial data showing no benefit over optimal medical therapy for most patients. Intervention is reserved for high-risk phenotypes (flash pulmonary edema, rapidly declining renal function with bilateral stenosis, truly refractory hypertension). See [[Renal and Mesenteric Artery Disease|Ch. 11]] for detailed criteria [@cooper2014coral, @astral2009].
Go to section in textbookDispute / Submit evidenceAll updates